UA112752C2 - Лікарський засіб та метод блокування утворення або посилення знищення білка p24 - Google Patents
Лікарський засіб та метод блокування утворення або посилення знищення білка p24Info
- Publication number
- UA112752C2 UA112752C2 UAA201300111A UAA201300111A UA112752C2 UA 112752 C2 UA112752 C2 UA 112752C2 UA A201300111 A UAA201300111 A UA A201300111A UA A201300111 A UAA201300111 A UA A201300111A UA 112752 C2 UA112752 C2 UA 112752C2
- Authority
- UA
- Ukraine
- Prior art keywords
- amplifying
- elimination
- inhibiting
- protein
- production
- Prior art date
Links
- 230000008030 elimination Effects 0.000 title abstract 2
- 238000003379 elimination reaction Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010041397 CD4 Antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Винахід стосується фармацевтичної композиції для блокування утворення або посилення знищення білка Р24, до складу якої входить активована потенційована форма антитіл до рецептора CD4 у суміші трьох гомеопатичних розведень С12, С30 та С50, причому активована потенційована форма антитіл до рецептора CD4 є формою до цілої молекули рецептора CD4 із послідовністю SEQ ID NO: 1, або до частини рецептора CD4 із послідовностями, вибраними з групи, що включає SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 та SEQ ID NO: 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010133046/15A RU2517084C2 (ru) | 2010-08-06 | 2010-08-06 | Способ и средство для ингибирования продукции или усиления элиминации белка р24 |
| PCT/IB2011/002355 WO2012017322A2 (en) | 2010-08-06 | 2011-07-15 | Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112752C2 true UA112752C2 (uk) | 2016-10-25 |
Family
ID=44899160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201300111A UA112752C2 (uk) | 2010-08-06 | 2011-07-15 | Лікарський засіб та метод блокування утворення або посилення знищення білка p24 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120263726A1 (uk) |
| JP (1) | JP2013535483A (uk) |
| CN (1) | CN103179987A (uk) |
| AU (1) | AU2011287286A1 (uk) |
| CA (1) | CA2807523A1 (uk) |
| DE (1) | DE112011102639T5 (uk) |
| EA (1) | EA029791B1 (uk) |
| ES (1) | ES2415029R1 (uk) |
| GB (1) | GB2496356A (uk) |
| IT (1) | ITTO20110636A1 (uk) |
| MX (1) | MX2013001450A (uk) |
| RU (1) | RU2517084C2 (uk) |
| SG (1) | SG187735A1 (uk) |
| UA (1) | UA112752C2 (uk) |
| WO (1) | WO2012017322A2 (uk) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181297C2 (ru) | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2309732C1 (ru) * | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
| EP2593474A2 (en) | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases |
| EP2593140A2 (en) | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | A method of increasing the effect of an activated-potentiated form of an antibody |
| MX2013000807A (es) | 2010-07-21 | 2013-10-28 | Oleg Iliich Epshtein | Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion. |
| RU2013111961A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2013111962A (ru) | 2013-03-18 | 2014-09-27 | Олег Ильич Эпштейн | Способ определения выраженности модифицирующей активности, ассоциированной с носителем |
| RU2603623C2 (ru) * | 2014-06-06 | 2016-11-27 | Олег Ильич Эпштейн | Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4311897A (en) | 1979-08-28 | 1982-01-19 | Union Carbide Corporation | Plasma arc torch and nozzle assembly |
| DE4236069A1 (de) * | 1992-10-26 | 1994-04-28 | Werner Dr Bergmann | Arzneimittel, insbesondere für orale Einnahme |
| US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| KR100667121B1 (ko) * | 1996-10-10 | 2007-01-12 | 프로브 인터내쇼날 | 바이러스 감염증 치료를 위한 조성물 및 방법 |
| WO2001016182A2 (en) * | 1999-08-27 | 2001-03-08 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE |
| WO2001043779A2 (en) * | 1999-12-16 | 2001-06-21 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
| RU2181297C2 (ru) * | 2000-06-20 | 2002-04-20 | Эпштейн Олег Ильич | Способ лечения патологического синдрома и лекарственное средство |
| RU2001134982A (ru) * | 2001-12-26 | 2004-02-20 | Олег Ильич Эпштейн | Способ коррекции иммунного ответа и лекарственное средство |
| AU2003246119B2 (en) * | 2002-06-28 | 2008-02-21 | Fuso Pharmaceutical Industries, Ltd. | Anti-HIV agent |
| UA76638C2 (en) | 2002-08-02 | 2006-08-15 | Oleh Illich Epshtein | Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon |
| UA76641C2 (uk) | 2002-08-02 | 2006-08-15 | Олєг Ільіч Епштєйн | Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози |
| CN100341573C (zh) * | 2002-09-27 | 2007-10-10 | 唐纳士公司 | 用于预防和治疗获得性免疫缺陷综合症的协同组合物 |
| GB2414670B (en) | 2003-03-14 | 2008-03-19 | Nutrition Res Inc | Homeopathic formulations useful for treating pain and/or inflammation |
| RU2393873C2 (ru) * | 2005-05-02 | 2010-07-10 | Майметикс Корпорейшн | Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2 |
| RU2315058C1 (ru) * | 2006-09-27 | 2008-01-20 | Институт органической химии Уфимского научного центра РАН | Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность |
| US20120263725A1 (en) * | 2010-08-06 | 2012-10-18 | Epshtein Oleg Iiiich | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV |
-
2010
- 2010-08-06 RU RU2010133046/15A patent/RU2517084C2/ru not_active IP Right Cessation
-
2011
- 2011-07-15 MX MX2013001450A patent/MX2013001450A/es unknown
- 2011-07-15 SG SG2013009022A patent/SG187735A1/en unknown
- 2011-07-15 US US13/135,897 patent/US20120263726A1/en not_active Abandoned
- 2011-07-15 UA UAA201300111A patent/UA112752C2/uk unknown
- 2011-07-15 AU AU2011287286A patent/AU2011287286A1/en not_active Abandoned
- 2011-07-15 JP JP2013522317A patent/JP2013535483A/ja active Pending
- 2011-07-15 DE DE112011102639T patent/DE112011102639T5/de not_active Withdrawn
- 2011-07-15 IT IT000636A patent/ITTO20110636A1/it unknown
- 2011-07-15 CA CA2807523A patent/CA2807523A1/en not_active Abandoned
- 2011-07-15 CN CN2011800388401A patent/CN103179987A/zh active Pending
- 2011-07-15 ES ES201390020A patent/ES2415029R1/es active Pending
- 2011-07-15 EA EA201300138A patent/EA029791B1/ru not_active IP Right Cessation
- 2011-07-15 WO PCT/IB2011/002355 patent/WO2012017322A2/en active Application Filing
- 2011-07-15 GB GB1303865.8A patent/GB2496356A/en not_active Withdrawn
-
2013
- 2013-05-15 US US13/894,476 patent/US20130315964A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GB201303865D0 (en) | 2013-04-17 |
| MX2013001450A (es) | 2013-10-25 |
| CA2807523A1 (en) | 2012-02-09 |
| EA029791B1 (ru) | 2018-05-31 |
| RU2010133046A (ru) | 2012-02-20 |
| WO2012017322A3 (en) | 2012-04-19 |
| SG187735A1 (en) | 2013-03-28 |
| EA201300138A1 (ru) | 2014-03-31 |
| US20130315964A1 (en) | 2013-11-28 |
| WO2012017322A2 (en) | 2012-02-09 |
| JP2013535483A (ja) | 2013-09-12 |
| DE112011102639T5 (de) | 2013-10-02 |
| ES2415029R1 (es) | 2013-09-17 |
| ES2415029A8 (es) | 2013-09-16 |
| US20120263726A1 (en) | 2012-10-18 |
| CN103179987A (zh) | 2013-06-26 |
| RU2517084C2 (ru) | 2014-05-27 |
| GB2496356A (en) | 2013-05-08 |
| ITTO20110636A1 (it) | 2012-02-07 |
| ES2415029A2 (es) | 2013-07-23 |
| AU2011287286A1 (en) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
| TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
| GB201303865D0 (en) | Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein | |
| PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
| MX2012007340A (es) | Anticuerpos anti/her3 y usos de los mismos. | |
| MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
| MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
| MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
| MA34091B1 (fr) | Anticorps anti-cd40 | |
| MX2013010360A (es) | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. | |
| MX2013001045A (es) | Organoide hepatico, sus usos y metodo de cultivo para obtenerlos. | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| MX2013009151A (es) | Inmunoterapia mejorada. | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| IN2012DN02793A (uk) | ||
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| PH12014502876A1 (en) | Pharmaceutical composition containing fimasartan and hydrochlorothiazide | |
| MX2015003034A (es) | Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso. | |
| MX2012010443A (es) | Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos. | |
| MX2012010317A (es) | ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO. | |
| MX2011006721A (es) | Formulacion farmaceutica de fenofibrato nanonizado. | |
| MX2014009015A (es) | Premezcla de potasio de raltegravir amorfo estable y proceso para la preparacion de la misma. | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| IN2012DE00826A (uk) |